AUG 10, 2016 10:15 AM PDT

Lower dose of beta blockers may save lives

"We set out on a mission to show if you treat patients with the doses that were used in the clinical trials, they will do better," says Jeffrey Goldberger. "We expected to see patients treated with the lower doses to have worse survival. We were shocked to discover they survived just as well, and possibly even better." (Credit: C x 2/Flickr)

Heart attack patients treated with a substantially lower dosage of beta-blockers survive at the same—or in some cases an even better—rate than patients on higher doses.

In fact, a new study shows that patients who receive one-fourth of the original clinical trial dose had up to a 20 to 25 percent decrease in mortality compared to the full dose group.

About 90 percent of patients who have had a heart attack currently receive beta-blockers, a class of drug commonly prescribed to improve survival and prevent future heart attacks. Beta-blockers block the effects of adrenaline on the heart, reduce irregular heartbeat (arrhythmia), and help prevent heart failure.

No one was more surprised at the results than lead investigator Jeffrey Goldberger, professor of medicine in cardiology at Northwestern University. He launched the study when he discovered heart attack patients were being treated with much lower doses of beta-blockers than were used in clinical trials.

“I thought that was terrible quality of care,” says Goldberger. “We set out on a mission to show if you treat patients with the doses that were used in the clinical trials, they will do better. We expected to see patients treated with the lower doses to have worse survival. We were shocked to discover they survived just as well, and possibly even better.”

He says new research should be conducted to determine the most appropriate beta-blocker dose for individual patients to get the optimal benefit. The earlier clinical trials did not assess the effects of different doses.

Patients are treated with lower doses for a variety of reasons. There may be concern about possible side effects that may include fatigue, sexual dysfunction, and depression. In addition, when patients are started on conservative, low doses in the hospital after a heart attack, they return home so quickly, there is little time to adjust the dosage.

The new study, published in the Journal of the American College of Cardiology, examined data in a multicenter registry on 6,682 patients who had a heart attack. About 90 percent were receiving beta-blockers. All the patients on beta-blockers survived longer than those who did not receive the drugs. The raw, unadjusted data showed that of the people who received the full dose, 14.7 percent died within two years; of those receiving the half dose, 12.9 percent died; for the quarter dose, 9.5 percent died; and for the one-eighth dose, 11.5 percent died.

OBTAIN (Outcomes of Beta-Blocker Therapy After Myocardial Infarction) is an observational multicenter registry in which beta-blocker dosing information was collected in patients with an acute heart attack at participating centers to assess the effect of dose on survival.

“There is probably not one right dose for every single patient,” Goldberger says. “It doesn’t make sense that the same dose will work for an 80-year-old frail man who had a small heart attack as a burly 40-year-old man with a huge heart attack.

“We now need to figure out how to dose it in individual patients. That’s something no one has considered in the decades that we have been using this medication. This huge gap in knowledge has been completely unexplored. Since this is medicine we use in every single heart attack patient, we ought to figure out how to use it properly.”

The National Heart, Lung and Blood Institute at the National Institutes of Health supported the work.

Source: Northwestern University

This article was originally published on futurity.org.
About the Author
MS
Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
FEB 15, 2022
Cardiology
Brushing and Flossing May Help You Live Longer
FEB 15, 2022
Brushing and Flossing May Help You Live Longer
Several studies have linked oral health and hygiene to longevity.
APR 26, 2022
Cardiology
Another Study Shows Alcohol Is Bad for the Heart
APR 26, 2022
Another Study Shows Alcohol Is Bad for the Heart
Several recent studies have shown that any amount of alcohol consumption raises cardiovascular disease risk.
MAY 03, 2022
Cardiology
Marathon Training Reduces Your Heart's Age
MAY 03, 2022
Marathon Training Reduces Your Heart's Age
First-time marathon runners in a 6-month training program saw major heart benefits in a recent study.
MAY 12, 2022
Clinical & Molecular DX
Researchers Show Influenza Directly Infects the Heart
MAY 12, 2022
Researchers Show Influenza Directly Infects the Heart
Heart complications are often observed in severe or fatal cases of Influenza. These problems can include electrical malf ...
JUL 18, 2022
Neuroscience
Lifestyle, More than Age, May Predict Dementia Risk
JUL 18, 2022
Lifestyle, More than Age, May Predict Dementia Risk
Multiple lifestyle risk factors for dementia may predict dementia risk more than age. The corresponding study was publis ...
AUG 04, 2022
Cardiology
Lifestyle Can Offset Genetic Stroke Risk
AUG 04, 2022
Lifestyle Can Offset Genetic Stroke Risk
Those who are genetically susceptible to stroke can lower their risk by as much at 43% through lifestyle choices.
Loading Comments...